Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International randomized double-blind study of rituximab retreatment regimens plus methotrexate in rheumatoid arthritis with inadequate response to methotrexate
2005-002396-33Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: ACR20 response at Week 48. Started Oct 2005; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-002396-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002396-33.